- Advertisement -spot_img
Wednesday, January 26, 2022

WHO approves two new treatments for coronavirus, including arthritis drug

WHO’s COVID treatment recommendations are updated regularly based on new data from clinical trials.

Paris:

The World Health Organization on Friday approved two new COVID-19 treatments, increasing its arsenal of vaccines as well as tools to prevent serious illness and virus deaths.

The news comes as Omicron cases fill hospitals around the world, with the WHO estimating that half of Europe will be infected by March.

In their recommendation in the British medical journal BMJ, WHO experts said the arthritis drug baricitinib, used with corticosteroids to treat severe or severe Covid patients, improved survival rates and reduced the need for ventilators.

The experts also recommended the synthetic antibody treatment sotrovimab for people with non-severe COVID-19 who are at highest risk of hospitalization, such as the elderly, people with immunodeficiencies or chronic diseases such as diabetes.

The benefits of sotrovimab for those at risk of hospitalization were deemed insignificant and the WHO said its effectiveness against newer variants such as Omicron was “still uncertain”.

Read Also:  The Governor of New York is announcing a significant drop in daily cases, a rare sign of hope.

Starting with corticosteroids for critically ill patients in September 2020, only three other treatments for COVID-19 have received WHO approval.

Corticosteroids are inexpensive and widely available and fight the inflammation that usually accompanies severe cases.

The arthritis drugs tocilizumab and serilumab, approved by the WHO in July, are IL-6 inhibitors that suppress a dangerous overreaction of the immune system to the SARS-CoV-2 virus.

Baricitinib is in a different class of drugs known as Janus kinase inhibitors, but it falls under the same guidelines as IL-6 inhibitors.

“When both are available, choose one based on issues including cost and the experience of the physician,” the guideline says.

The synthetic antibody treatment Regeneron was approved by the WHO in September and the guidelines say sotrovimab can be used for the same type of patients.

WHO’s COVID treatment recommendations are updated regularly based on new data from clinical trials.

(Except for the title, this story has not been edited by NDTV staff and is published from a syndicated feed.)

,

World Nation News Deskhttps://www.worldnationnews.com
World Nation News is a digital news portal website. Which provides important and latest breaking news updates to our audience in an effective and efficient ways, like world’s top stories, entertainment, sports, technology and much more news.
Latest news
Related news
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here